Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study

Domı́nguez, A.; Márquez, Antonia; Gumà, Josep; Llanos, Marta; Herrero, J.; Nieves, M; Miramón, José; Alba, Emilio

doi:10.1093/annonc/mdh465

Cited by 69 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A nonrandomized study from Spain demonstrated a PFS rate of 87% and an OS rate of 97% at 78 months in 80 unselected patients with nonbulky stage I and II HL treated in 1990 -2002 with six cycles of ABVD alone, results similar to the MSKCC experience [26]. In a recent retrospective review of 74 patients with nonbulky stage IA, IIA, and IIB HL from the Dana-Farber Cancer Institute treated with chemotherapy only in 1992-2007 (six ABVD, 70 patients; four ABVD, two patients; two ABVD and two etoposide, vinblastine, and doxorubicin, two patients; four ABVD and two doses doxorubicin, two patients), there were no deaths, and the PFS rate at a median follow-up time of 52 months was 90.5% [27].…”

Section: Chemotherapy Alone In the Treatment Of Nonbulky Early-stage Hlsupporting

confidence: 58%

The Case for Chemotherapy Only for Localized Hodgkin Lymphoma

Straus

2009

The Oncologist

View full text Add to dashboard Cite

Although radiation therapy (RT) alone, and more recently in combination with chemotherapy, has been the cornerstone of curative treatment for early-stage Hodgkin lymphoma for >40 years, the late toxicities of this treatment are increasingly being recognized as causes of significant late morbidity and mortality. In recent years, the focus of treatment of early-stage Hodgkin lymphoma has been reductions in the doses and fields of RT and attempts to reduce the amount and the toxicity of chemotherapy. Another approach has been to treat with chemotherapy alone and to eliminate RT entirely unless it is absolutely necessary. This review summarizes the accumulating information on the late side effects of treatment of Hodgkin lymphoma, the results of trials with chemotherapy only, attempts to reduce the toxicity of chemotherapy, and the new role of positron emission tomography in treatment planning.

show abstract

Section: Chemotherapy Alone In the Treatment Of Nonbulky Early-stage Hlsupporting

confidence: 58%

The Case for Chemotherapy Only for Localized Hodgkin Lymphoma

Straus

2009

The Oncologist

View full text Add to dashboard Cite

show abstract

“…The frequency of grade 3 or 4 neutropenia—defined by National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) as an absolute neutrophil count (ANC) of <1.0–0.5 × 10 9 /L and <0.5 × 10 9 /L, respectively—in randomized trials involving ABVD chemotherapy ranges from 10 and 66% [13, 19, 20]. The wide range of the occurrence of this problem possibly reflects the varied number of treatment cycles administered in these trials.…”

Section: Abvd and Neutropeniamentioning

confidence: 99%

“…While most ABVD-based clinical trials initiated prior to the introduction of GFs relied on dose alterations as the prime strategy to counter neutropenia, subsequent studies relied on GFs as the preferred way to maintain dose intensity and to prevent neutropenia-related complications [14, 16, 20, 21]. Both granulocyte colony stimulating factor (G-CSF) and granulocyte macrophage colony stimulating factor (GM-CSF) have been used to manage neutropenia in cancer chemotherapy, but neither of them is found to be superior to the other [30].…”

Section: Abvd and Neutropeniamentioning

confidence: 99%

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

Vakkalanka

Link

2011

Advances in Hematology

View full text Add to dashboard Cite

A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter this commonly encountered problem, including dose modification, use of colony stimulating factors, and prophylactic or therapeutic use of antibiotics. Data to support these approaches is somewhat controversial, and in keeping with the paucity of definitive evidence, there is a wide disparity in the management of neutropenia in patients receiving ABVD chemotherapy. This paper summarizes the evidence for managing ABVD-related neutropenia during the treatment of Hodgkin lymphoma.

show abstract

“…In a single-arm phase II trial, Rueda Dominguez et al treated 95 patients with six cycles of ABVD in early-stage HL [37]. Patients were relatively young (median age of 30 years), most had stage II disease (61%), and in total 48% were unfavorable by EORTC criteria.…”

Section: Outcomes After Modifications In Therapymentioning

confidence: 99%

Can Low-Risk, Early-Stage Patients with Hodgkin Lymphoma Be Spared Radiotherapy?

Coté

Canellos

2011

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Advances in the treatment of Hodgkin lymphoma since about 1970 have led to a remarkable improvement in the long-term outcomes of what was once considered an incurable disease. The prolonged survival of cured patients has revealed new issues concerning the toxicity of successful therapy, however, including an increased risk of secondary malignancies and end-organ damage such as heart disease. This concern has led to the clinical research question of whether the de-escalation of treatment intensity could allow high cure rates to continue with less long-term toxicity. In young patients with favorable early-stage disease, the challenge has been to use systemic therapy while omitting radiation therapy as part of the initial treatment. This review briefly summarizes past data and updates readers regarding recent publications on this topic.

show abstract

Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study

Abstract: The administration of six ABVD cycles is an effective and safe treatment in patients with stage I and II Hodgkin's lymphoma.

Cited by 69 publications

References 33 publications

The Case for Chemotherapy Only for Localized Hodgkin Lymphoma

The Case for Chemotherapy Only for Localized Hodgkin Lymphoma

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

Can Low-Risk, Early-Stage Patients with Hodgkin Lymphoma Be Spared Radiotherapy?

Contact Info

Product

Resources

About